Page 5 - Interventional Cardiovascular Programs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Triglyceride-lowering medication may lower stroke risk in people with heart disease Taking the triglyceride-lowering medication icosapent ethyl cut the risk of stroke by an additional 36% in people at increased risk of cardiovascular disease who already have their bad cholesterol levels under control using statin medications, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2021. The virtual meeting is March 17-19, 2021 and is a world premier meeting for researchers and clinicians dedicated to the science of stroke and brai...

The two paired trials evaluated sotagliflozin, a drug that inhibits SGLT2 and SGLT1, according to a study published in <em>The New England Journal of Medicine</em>.

Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results December 14, 2020 05:00 ET | Source: Amarin Corporation plc Amarin Corporation plc Bedminster, New Jersey, UNITED STATES REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers VASCEPA COVID-19 CardioLink-9 Randomized Tri...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 ... Amarin Corporation plcDecember 13, 2020 GMT VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VASCEPA loading dose VASCEPA administration resulted in a significant 52% reduct...